Passage Bio announces that Maxine Gowen, Ph.D., will be chair of the board of directors | Your money
PHILADELPHIA, September 07, 2021 (GLOBE NEWSWIRE) – Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic drug company focused on the development of transformative therapies for central nervous system (CNS) disorders, announced today that Maxine Gowen, Ph.D., has been appointed Chair of the Company’s Board of Directors, effective August 31.
Dr Gowen is an accomplished biopharmaceutical executive with extensive operational and research and development experience. Dr Gowen has been a member of the Board of Directors of Passage Bio since February 2021 and currently sits on the Nomination and Corporate Governance Committee. She will continue to sit on this committee in her capacity as Chair of the Board of Directors.
“I am delighted that Maxine is leading our Board of Directors following the unexpected passing of our former President, Dr. Tadataka Yamada,” said Bruce Goldsmith, Ph.D., President and CEO (CEO), Passage Organic. “With over 30 years of experience in pharmaceutical and biotechnology research and as CEO, Maxine is extremely well qualified for the role of President. His experience will be invaluable to Passage Bio as we move our strong pipeline of transformative drugs forward through clinical development with the goal of getting them to the patients who need them as quickly as possible. “
Dr Gowen said, “I am honored to continue the work started by Tachi Yamada as I assume the role of Chair of the Board of Directors of Passage Bio. This is a unique company with enormous promise in developing truly innovative genetic drugs for patients with devastating CNS disorders with few treatment options. I couldn’t be more excited to be a part of Passage Bio’s journey at such a pivotal stage in its evolution.
Dr Gowen is the CEO of Tamuro Bio, a position she has held since July 2019. Prior to Tamuro Bio, she was the Founding President and CEO of Trevena, Inc. from 2007 to October 2018. Previously, she held various executive positions at GlaxoSmithKline, GSK, over a period of 15 years. As senior vice president of the GSK Center of Excellence for Drug Discovery, she developed an innovative new approach to outsource drug discovery. She also currently sits on the boards of Aclaris Therapeutics, Inc., Idera Pharmaceuticals, Inc., Merus NV and the privately held Tamuro Bio.
Dr Gowen obtained a B.Sc. in Biochemistry from the University of Bristol, UK, obtained a PhD. in Cell Biology from the University of Sheffield, UK, and received an MBA from the Wharton School, University of Pennsylvania.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we’re on a mission to deliver life-transforming genetic medicines for CNS patients who replace their suffering with limitless possibilities, while building lasting relationships with the communities we serve. . Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned Gene Therapy Program at the University of Pennsylvania to conduct our discovery and preclinical work enabling IND. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations which we then combine with our in-depth clinical, regulatory, manufacturing and commercial expertise to rapidly advance our strong pipeline of gene therapies optimized for clinical trials. As we work with speed and tenacity, we are always attentive to the patients who can benefit from our therapies. More information is available at www.passagebio.com.
For more information, please contact:
Investors: Stuart Henderson Passage Bio 267.866.0114 [email protected]
Media: Gwen Fisher Passage Bio 215.407.1548 [email protected]
Copyright 2021 GlobeNewswire, Inc.